190 related articles for article (PubMed ID: 9279505)
1. Trovafloxacin.
Haria M; Lamb HM
Drugs; 1997 Sep; 54(3):435-45; discussion 446. PubMed ID: 9279505
[TBL] [Abstract][Full Text] [Related]
2. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
Pechère JC; Gootz TD
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
[TBL] [Abstract][Full Text] [Related]
3. Gemifloxacin.
Lowe MN; Lamb HM
Drugs; 2000 May; 59(5):1137-47; discussion 1148. PubMed ID: 10852645
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
Felmingham D; Robbins MJ; Ingley K; Mathias I; Bhogal H; Leakey A; Ridgway GL; Grüneberg RN
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
7. Trovafloxacin: a new fluoroquinolone.
Alghasham AA; Nahata MC
Ann Pharmacother; 1999 Jan; 33(1):48-60. PubMed ID: 9972385
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
Verbist L; Verhaegen J
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):683-5. PubMed ID: 8894581
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.
Lacy MK; Nicolau DP; Banevicius MA; Nightingale CH; Quintiliani R
J Antimicrob Chemother; 1999 Oct; 44(4):477-81. PubMed ID: 10588309
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Ernst ME; Ernst EJ; Klepser ME
Am J Health Syst Pharm; 1997 Nov; 54(22):2569-84. PubMed ID: 9397218
[TBL] [Abstract][Full Text] [Related]
15. Double-blind comparison of trovafloxacin and doxycycline in the treatment of uncomplicated Chlamydial urethritis and cervicitis. Trovafloxacin Chlamydial Urethritis/Cervicitis Study Group.
McCormack WM; Dalu ZA; Martin DH; Hook EW; Laisi R; Kell P; Pluck ND; Johnson RB
Sex Transm Dis; 1999 Oct; 26(9):531-6. PubMed ID: 10534208
[TBL] [Abstract][Full Text] [Related]
16. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Yong DE; Cheong HJ; Kim YS; Park YJ; Kim WJ; Woo JH; Lee KW; Kang MW; Choo YS
J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
[TBL] [Abstract][Full Text] [Related]
20. The chemistry and biological profile of trovafloxacin.
Brighty KE; Gootz TD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():1-14. PubMed ID: 9222064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
